Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jessica Janes"'
Autor:
Victor Pereira, Taofik Oyekunle, Jessica Janes, Christopher J. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Zachary Klaassen, Stephen J. Freedland, Adriana C. Vidal, Ilona Csizmadi
Publikováno v:
The Prostate.
Autor:
Danny Long, Jessica Janes, Ruixin Yang, Erika Williamson, Kelly Bree, Aditya Srinivasan, Amanda Dehoedt, Stephen Freedland, Stephen Williams
Publikováno v:
Journal of Urology. 209
Autor:
Stephen Williams, Jessica Janes, Lauren Howard, Amanda DeHoedt, Jacques Baillargeon, Yong-Fang Kuo, Douglas Tyler, Martha Terris, Stephen Freedland
Publikováno v:
Journal of Urology. 209
Autor:
Kelly Bree, Jessica Janes, Ruixin Yang, Patrick Hensley, Aditya Srinivasan, Amanda DeHoedt, Sanjay Das, Stephen Freedland, Stephen Williams
Publikováno v:
Journal of Urology. 209
Autor:
Jun Gong, Jessica Janes, Anoruo Asilonu, Claire Trustram Eve, Shannon R. Stock, Justin Waller, Amanda Marie De Hoedt, Jeri Kim, Sameer R. Ghate, Irene M Shui, Stephen J. Freedland
Publikováno v:
Journal of Clinical Oncology. 41:92-92
92 Background: Oligometastatic hormone-sensitive prostate cancer (omHSPC) represents an advanced prostate cancer subset where metastasis-directed therapy (MDT) and prostate radiation therapy (RT) may improve clinical response and outcomes; however, t
Publikováno v:
Journal of surgical education. 79(1)
OBJECTIVE Individuals with Impostor Phenomenon (IP) believe they have achieved success by fooling others into thinking they are intelligent/capable and fear they will be discovered. This fear has been shown to cause psychological distress and may aff
Autor:
Patrick Tamukong, Paige Kuhlmann, Sungyong You, Shengchen Su, Yanping Wang, Eric Jay Small, Brian I. Rini, Susan Halabi, Jessica Janes, Stephen J. Freedland, Hyung Lae Kim
Publikováno v:
Journal of Clinical Oncology. 40:370-370
370 Background: Clear cell renal cell carcinoma (ccRCC) is characterized by defects in the Von Hippel-Lindau/hypoxia-inducible factor (VHL/HIF) pathway. Several FDA-approved RCC therapies target the products of HIF-response genes. HIF2A is a promisin
Autor:
Jessica Janes
Publikováno v:
Daily Mail. 5/20/2024, p22. 1p.
Publikováno v:
Journal of Vascular Surgery: Venous and Lymphatic Disorders. 8:333
Publikováno v:
In Journal of Vascular Surgery: Venous and Lymphatic Disorders March 2020 8(2):333-333